Clinical Cancer Research  Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, B.
Right arrow Articles by Markowitz, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, B.
Right arrow Articles by Markowitz, S. D.

Clinical Cancer Research, Vol 2, Issue 10 1639-1647, Copyright © 1996 by American Association for Cancer Research


ARTICLES

Wild-type p53 demonstrates functional dominance in a human colon carcinoma cell line in which it induces reversible growth arrest

B Yang, PJ Stambrook and SD Markowitz
Departments of Molecular Biology & Microbiology and Medicine, Case Western Reserve University and Ireland Cancer Center, University Hospitals of Cleveland, Cleveland, Ohio 44106, USA.

We have introduced an inducible wild-type p53 allele into the human SW480 colon cancer cell line, which bears an endogenous mutant p53 allele. The expression of inducible wild-type p53 is under basal repression by the lac repressor and is induced by isopropyl-beta-thiogalactopyranoside. The addition of isopropyl-beta-thiogalactopyranoside induces expression of wild-type p53 transcript and protein at a level no greater than that of the endogenous mutant p53. This level of wild-type p53 induction is sufficient both to induce expression of WAF1/CIP1 and to induce G1 cell cycle arrest. This p53-induced growth arrest is reversible after 6 days of continuous p53 expression, indicating that apoptosis is not induced. These results demonstrate that in a human colon epithelial cell background, wild-type p53 is functionally dominant over this mutant p53 and thus provides a mechanism for the observed inactivation of both copies of the p53 gene in most colon cancers. Moreover, despite the well-documented role of apoptosis in maintaining homeostasis in the nontransformed colon epithelium, these results demonstrate that restoration of wild-type p53 expression is insufficient to trigger apoptosis of transformed colonic cells.


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
M. Narimatsu, Y. Nagayama, K. Akino, M. Yasuda, T. Yamamoto, T.-t. Yang, A. Ohtsuru, H. Namba, S. Yamashita, H. Ayabe, et al.
Therapeutic Usefulness of Wild-Type p53 Gene Introduction in a p53-Null Anaplastic Thyroid Carcinoma Cell Line
J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3668 - 3672.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1996 by the American Association for Cancer Research.